NextBiomedical investment analysis. Nexpowder hemostatic agent in commercialization phase across 30+ countries via Medtronic. Nexphere-F absorbable embolization microsphere in US pivotal trial with FDA Breakthrough Device Designation. 2025 revenue KRW 16.5B, OP loss KRW 735M. HS code export data-based Q1 2026 estimates and analyst target price reverse-engineering.
Deep-dive on Pharma Research Products (214450.KQ), the Korean KOSDAQ company behind Rejuran PDRN skin boosters riding the global K-beauty aesthetics wave.
Deep-dive into Samsung Electronics (005930.KS): HBM memory, Galaxy, and foundry ambitions—what global investors need to know about Korea's tech crown jewel.
KOSPI closed in selective risk-on mode on April 10, with Samsung Electro-Mechanics surging 9.5% and telecom infrastructure stocks driving the day's narrative.